<SEC-DOCUMENT>0001104659-20-118204.txt : 20201026
<SEC-HEADER>0001104659-20-118204.hdr.sgml : 20201026
<ACCEPTANCE-DATETIME>20201026170523
ACCESSION NUMBER:		0001104659-20-118204
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201026
DATE AS OF CHANGE:		20201026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		201261348

	BUSINESS ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2034243-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):&nbsp;<B>October
26, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Catabasis Pharmaceuticals,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-37467</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-3687168</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>100 High Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>28th Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boston, Massachusetts</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>02110</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code:&nbsp;<B>(617) 349-1971</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form&nbsp;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I>
General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Securities registered pursuant to Section&nbsp;12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 34%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which<BR>
registered</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.001 par value per share</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">CATB</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in">Item&nbsp;2.02</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Results of Operations and Financial Condition.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 26, 2020, Catabasis Pharmaceuticals,
Inc. (the &#8220;Company&#8221;) issued a press release announcing that the Company had cash and cash equivalents of approximately
$52.9 million as of September 30, 2020 (unaudited).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in">Item&nbsp;8.01</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Other Events.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the October 26, 2020 press release, the
Company announced top-line results from its Phase 3 PolarisDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in">Item&nbsp;9.01</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> Financial Statements and Exhibits.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit<BR>
Number</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tm2034243d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2034243d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release issued October 26, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CATABASIS PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: October 26, 2020</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Ben Harshbarger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Ben Harshbarger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">SVP, General Counsel</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2034243d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2034243d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Catabasis Pharmaceuticals Announces Top-Line
Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><I>--
PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints --</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #545454"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>BOSTON, MA, OCTOBER 26, 2020 &ndash;
</B><U>Catabasis Pharmaceuticals, Inc.</U> (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the
Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a
change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo<FONT STYLE="background-color: white">.
The secondary endpoint timed function tests (time to stand, 10-meter walk/run and 4-stair climb) also did not show statistically
significant improvements. </FONT>Edasalonexent was observed to be generally safe and well-tolerated in this trial. Catabasis is
stopping activities related to the development of edasalonexent including the ongoing GalaxyDMD open-label extension trial. The
Company plans to work with external advisors to explore and evaluate strategic options going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;We are deeply saddened and disappointed
by the results of our Phase 3 PolarisDMD trial,&rdquo; said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. &ldquo;I
want to sincerely thank all of the boys, their families and caregivers, investigators and the trial sites that participated in
and enabled this program. The entire Catabasis team has worked tirelessly to find a treatment for this progressive disease. We
hope that our data and work to date can be used to benefit ongoing and future research in DMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Phase 3 trial was a one-year placebo-controlled
trial designed to evaluate the safety and efficacy of edasalonexent in boys ages 4-7 (up to 8th birthday) with DMD. The global
trial enrolled 131 boys across eight countries, with any mutation type, who were not on steroids. Edasalonexent was well-tolerated,
consistent with the safety profile seen to date. The majority of adverse events were mild in nature and the most common treatment-related
adverse events were diarrhea, vomiting, abdominal pain and rash. There were no treatment-related serious adverse events and no
dose reductions.&nbsp;The global COVID-19 pandemic had no meaningful impact on the trial or its results. Data from the PolarisDMD
trial will be further analyzed and are expected to be presented at an upcoming scientific conference and published.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;These results are disheartening
for the Duchenne community, and specifically for the boys who participated in this trial and their families. However, the results
contribute to the natural history data of Duchenne and add to the knowledge base that will one day produce a foundational, long-term
therapy for this disease,&rdquo; said Pat Furlong, Founding President and Chief Executive Officer of Parent Project Muscular Dystrophy
(PPMD). &ldquo;The continued advancement of research and the development of possible treatment options will remain of critical
importance to our community. We appreciate Catabasis&rsquo; efforts and commitment to every family that is or has ever been affected
by Duchenne.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company expects to report Q3 2020 financials
in November of 2020. As of September 30, 2020, Catabasis had cash and cash equivalents of approximately $52.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Catabasis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Catabasis Pharmaceuticals is a clinical-stage
biopharmaceutical company. Our mission is to bring hope and life-changing therapies to patients and their families.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any statements in this press release about
future expectations, plans and prospects for the Company, including statements about its exploration and evaluation of strategic
options, the termination of activities related to the edasalonexent program, including the ongoing GalaxyDMD open-label extension
trial, and plans to publish data from the Phase 3 PolarisDMD trial, and other statements containing the words &ldquo;believes,&rdquo;
 &ldquo;anticipates,&rdquo; &ldquo;plans,&rdquo; &ldquo;hopes,&rdquo; &ldquo;expects,&rdquo; and similar expressions, constitute
forward-looking statements within the meaning of applicable securities laws and regulations.&nbsp; Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties
related to: the impact of the COVID-19 pandemic and the effectiveness of the steps we have implemented to address the pandemic;
the availability of funding sufficient for the Company&rsquo;s foreseeable and unforeseeable operating expenses and capital expenditure
requirements; unexpected costs or expenses that arise during the termination of activities related to the edasalonexent program;
risks inherent in the Company&rsquo;s exploration, evaluation and implementation of its review of strategic options; and general
market and economic conditions; and other factors discussed in the &ldquo;Risk Factors&rdquo; section of the Company&rsquo;s Quarterly
Report on Form 10-Q for the period ended June 30, 2020, which is on file with the Securities and Exchange Commission, and in other
filings that the Company may make with the Securities and Exchange Commission in the future.&nbsp; In addition, the forward-looking
statements included in this press release represent the Company&rsquo;s views as of the date of this press release. The Company
anticipates that subsequent events and developments will cause the Company&rsquo;s views to change.&nbsp; However, while the Company
may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as representing the Company&rsquo;s views as of any date subsequent
to the date of this release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Catabasis Contacts:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrea Matthews</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>investors@catabasis.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elizabeth Higgins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>media@catabasis.com</U></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2034243d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2034243d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T ,H# 2(  A$! Q$!_\0
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M?5<PM&-&HJKE2AT%%%%=9]H%%%% !1110 4444 %%%% !1110 4444 %%%%
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MP;+2/$6MP'2X/$3ZIAOLT_AB&\G\0V2X_P!)O=+M[7*^>6'\D&F?\$ _VQ-
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M$?%FLZGJ7CW3OA]9SQC5/#P\2W^J:WJD8UN5HGEUN7R9$::&*@35TUW/D/\
MX,YK.^LOCG_P4[TJZO+?4-5M/AY\--*N=5T_B'4]2L_&OQ7LO[3L=PS]GUF:
M2.]M,8)(3!(.#\!_\&GOP\^"WQ#_ ."L7B&/XKZ3X9UO6_"?[/\ \5O&OP8T
M[Q%80ZG8M\1M-^(7PYL!?Z/97 :%_$^D>!)?&&J/.ZEK..TDNX\/"*_JF_X(
MA?\ !#?XN_\ !)KXO_M6>)O$/QJ\"_%3P)\<_!^F^&O#<FE:3J=IK^EW'A7Q
M;K-_X6U+Q);Z@([6:1]&U_5Y?$@24^;JHW6[M@,/Q^^ O_!HS^UU\&O&VJ?%
MGPK^W9X0^&GQ7\'V\_B'X.>+/ACIGB>UO]-\9R7\#VUCXQN=37SCX>E\.WFI
MZ8T&DEEFDN!',AM99,A*A9IWZ]O^">^?\'GG@#X)6G[.'[*'Q4GL=%T;]H(_
M'/4O#.B:EIUKIMIXNUGX0V?PY\3ZYXKM[R_B+7.H0:'XIM_!=SIRA]FG7?B*
M.YVA;>1WWO\ @I#_ ,%#?V5/@=^RY_P2K^'G[4W[&G@[]MS]N_XD?LG_ +/_
M (N\+>#OB7;2/IOA"3XB>#?!N@ZMXGNM?AC,MYK/C7XB^%XM#2.%_,:[T,%R
MD:OYWFFD_P#!MK_P4>_;"_:@^'?Q4_X*E_MIZ+\8_A]\+]?T:Y&F6]QJ?B35
M_%'A/2]=M=<U;PSH>EW2)9:#I'B)[*+1]0E8K(;"^NWAB,AC4_IO_P %RO\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
